Yearly Archives: 2018

Antibiotic companies seek success by learning from each others’ failures

San Diego's Forge Therapeutics will get information from another company’s unsuccessful effort to develop antibiotics, under a new government-sponsored initiative to help others ...

Antibiotic companies seek success by learning from each others’ failures2018-09-26T10:54:30-07:00

ASM Microbe 2018 LB19 “Improved Gram-negative Antibacterial Activity Upon Combination of LpxC Inhibitor FG-944 and RNA Polymerase Inhibitors (Rifampin or APY281)

ASM Microbe 2018 LB19 “Improved Gram-negative Antibacterial Activity Upon Combination of LpxC Inhibitor FG-944 and RNA Polymerase Inhibitors (Rifampin or APY281)2018-06-12T15:43:14-07:00

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David ...

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting2018-04-09T06:55:22-07:00
Load More Posts
Go to Top